These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 4083271)

  • 41. Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial.
    Gebbia V; Testa A; Valenza R; Cannata G; Tirrito ML; Gebbia N
    Cancer; 1995 Nov; 76(10):1821-8. PubMed ID: 8625054
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Randomized, double-blind comparison of a prochlorperazine-based versus a metoclopramide-based antiemetic regimen in patients undergoing autologous bone marrow transplantation.
    Gilbert CJ; Ohly KV; Rosner G; Peters WP
    Cancer; 1995 Dec; 76(11):2330-7. PubMed ID: 8635039
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group.
    Rubenstein EB; Gralla RJ; Hainsworth JD; Hesketh PJ; Grote TH; Modiano MR; Khojasteh A; Kalman LA; Benedict CR; Hahne WF
    Cancer; 1997 Mar; 79(6):1216-24. PubMed ID: 9070501
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metoclopramide. A review of antiemetic trials.
    Gralla RJ
    Drugs; 1983 Feb; 25 Suppl 1():63-73. PubMed ID: 6682376
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy.
    Fraschini G; Ciociola A; Esparza L; Templeton D; Holmes FA; Walters RS; Hortobagyi GN
    J Clin Oncol; 1991 Jul; 9(7):1268-74. PubMed ID: 1828499
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis.
    Bhatia A; Tripathi KD; Sharma M
    Indian J Med Res; 2004 Sep; 120(3):183-93. PubMed ID: 15489556
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
    Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
    J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase II trials of ondansetron with high-dose cisplatin.
    Kris MG
    Semin Oncol; 1992 Aug; 19(4 Suppl 10):23-7. PubMed ID: 1387247
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron.
    du Bois A; Meerpohl HG; Vach W; Kommoss FG; Fenzl E; Pfleiderer A
    Eur J Cancer; 1992; 28(2-3):450-7. PubMed ID: 1534250
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antiemetic efficacy of prochlorperazine, haloperidol, and droperidol in cisplatin-induced emesis.
    Owens NJ; Schauer AR; Nightingale CH; Golub GR; Martin RS; Williams HM; Schauer PK
    Clin Pharm; 1984; 3(2):167-70. PubMed ID: 6373102
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized crossover antiemetic study in cisplatin-treated patients. Comparison between high-dose i.v. metoclopramide and high-dose i.v. dexamethasone.
    Frustaci S; Grattoni E; Tumolo S; Crivellari D; Figoli F; Galligioni E; Veronesi A; Tirelli U; Grigoletto E
    Cancer Chemother Pharmacol; 1986; 17(1):75-9. PubMed ID: 3698180
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase I and other dose-ranging studies of ondansetron.
    Grunberg SM
    Semin Oncol; 1992 Aug; 19(4 Suppl 10):16-22. PubMed ID: 1387246
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis.
    Sorbe BG; Högberg T; Glimelius B; Schmidt M; Wernstedt L; Hansen O; Sörensen BT; Räisänen I; van Oosterom AT; de Bruijn KM
    Cancer; 1994 Jan; 73(2):445-54. PubMed ID: 8293412
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study.
    Khojasteh A; Sartiano G; Tapazoglou E; Lester E; Gandara D; Bernard S; Finn A
    Cancer; 1990 Sep; 66(6):1101-5. PubMed ID: 2144788
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The antiemetic efficacy of granisetron plus dexamethasone, haloperidol and loracepam in breast cancer patients treated with high-dose chemotherapy with peripheral blood stem-cell support.
    Climent MA; Palau J; Ruiz A; Soriano V; Aznar E; Olmos T; Guillem V
    Support Care Cancer; 1998 May; 6(3):287-90. PubMed ID: 9629884
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative evaluation of the clinical efficacy and safety of ondansetron and metoclopramide in the prophylaxis of emesis induced by cancer chemotherapy regimens including cisplatin.
    Advani SH; Gopal R; Dhar AK; Lal HM; Cooverji ND
    J Assoc Physicians India; 1996 Feb; 44(2):127-30. PubMed ID: 10999066
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomized comparative study of antiemetic prophylaxis with ondansentron in a single 32-mg loading dose versus 8 mg every 6 h in patients undergoing cisplatin-based chemotherapy.
    Tsavaris N; Fountzilas G; Mylonakis N; Athanassiadis A; Kosmas C; Karakousis C; Bacoyiannis C; Kosmidis P
    Oncology; 1998; 55(6):513-6. PubMed ID: 9778615
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Levonantradol for the treatment of chemotherapy-induced nausea and vomiting.
    Gerhartz HH; Binsack T; Hiller E
    Klin Wochenschr; 1983 Jul; 61(14):719-21. PubMed ID: 6350696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.